Amplification of the MYCN gene (MNA) is observed in approximately 25 to 35% of neuroblastoma patients, and is a well-recognized marker of tumor aggressiveness and poor outcome. Targeting MYCN is a novel therapy strategy to induce tumor regression. Here, we discovered that a BIRC5/Survivin inhibitor, YM155, specifically inhibits MNA neuroblastoma cell growth in vitro. We found that YM155 promotes MYCN degradation in MNA cells. Further, we found that YM155 inhibits USP7 deubiquitinase activity in vitro, using Ub-aminomethylcoumarin (Ub-AMC) as substrate. Results from in vivo studies further demonstrated that YM155 significantly inhibited the tumor growth in MNA neuroblastoma xenograft model. Our data support a novel mechanism of action of YM155 in inhibition of growth of cancer cells through inducing MYCN degradation by inibition of activity of deubiquitinase like USP7.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejps.2022.106343 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Disruption of survivin protein expression by treatment with YM155 accelerates the resolution of neutrophilic inflammation.
Br J Pharmacol
November 2024
Departamento de Morfologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Background And Purpose: Prolonged survival of neutrophils is essential for determining the progression and severity of inflammatory and immune-mediated disorders, including gouty arthritis. Survivin, an anti-apoptotic molecule, has been described as a regulator of cell survival. This study aims to examine the effects of YM155 treatment, a survivin selective suppressant, in maintaining neutrophil survival in vitro and in vivo experimental settings of neutrophilic inflammation.
View Article and Find Full Text PDFMolecular Insights into the Anticancer Activity of Withaferin-A: The Inhibition of Survivin Signaling.
Cancers (Basel)
September 2024
AIST-INDIA DAILAB, National Institute of Advanced Industrial Science & Technology (AIST), Central 4-1, Tsukuba 305-8565, Japan.
Article Synopsis
- Survivin is a protein that helps prevent cell death, and scientists are looking for ways to block it to fight cancer.
- Wi-A is a natural compound from Ashwagandha leaves that can stop Survivin from working, similar to some expensive synthetic drugs.
- Tests on cancer cells showed that Wi-A-rich extract, called Wi-AREAL, can slow down cell growth and trigger cell death, making it a promising option for treating cancer.
Survivin inhibition attenuates EGF-induced epithelial mesenchymal transformation of human RPE cells via the EGFR/MAPK pathway.
PLoS One
August 2024
Faculty of Life Sciences and medicine, Northwest University, Xi'an, Shaanxi Province, China.
Purpose: The abnormal growth factors-induced epithelial-mesenchymal transition (EMT) in retinal pigment epithelial (RPE) cells was known as a vital pathogenesis of proliferative vitreoretinopathy (PVR). This study aims to explore how survivin inhibition affects EMT induced by epidermal growth factor (EGF) in RPE cells.
Methods: Human primary RPE cells were identified in vitro.
SIRT6 suppresses colon cancer growth by inducing apoptosis and autophagy through transcriptionally down-regulating Survivin.
Mitochondrion
September 2024
Department of Health Management, The Third Xiangya Hospital, Central South University, Changsha, China; Department of Laboratory Medicine, the Third Xiangya Hospital, Central South University, Changsha, China. Electronic address:
SIRT6, an evolutionarily conserved histone deacetylase, has been identified as a novel direct downstream target of Akt/FoxO3a and a tumor suppressor in colon cancer in our previous research. Nevertheless, the precise mechanisms through which SIRT6 hinders tumor development remain unclear. To ascertain whether SIRT6 directly impacts Survivin transcription, a ChIP assay was conducted using an anti-SIRT6 antibody to isolate DNA.
View Article and Find Full Text PDFCorrigendum to "Inhibition of Sp1-mediated survivin and MCL1 expression cooperates with SLC35F2 and myeloperoxidase to modulate YM155 cytotoxicity to human leukemia cells" [Biochem. Pharmacol.188 (2021) 114544].
Biochem Pharmacol
August 2024
Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung 804, Taiwan; Department of Biotechnology, Kaohsiung Medical University, Kaohsiung 807, Taiwan. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!